主持和参与国家级课题3项、省部级课题40余项，国际合作项目5项，联合出版专著15部，在国内外期刊发表文章50余篇，获日本废弃物学会优秀成果奖1 次、年度优秀论文奖1次。参与起草《促消费扩内需对策研究报告》《消费品工业"三品"专项行动实施效果评估报告》《关于开展工业产品生态设计的指 导意见》《中国降低荧光灯含汞量路线图》等多项重要技术报告和政策规划文件。 赛迪智库·消费品工业研究所 李博洋 消费品工业研究所 所长 长期从事消费品工业高质量发展、工业产品绿色设计、工业绿色低碳转型等领域的管理政策研究、产业规划制定与战略决策咨询等工作。 生物制造，是"十五五"规划《建议》提出的六大未来产业之一。什么是生物制造？它又能干什么？比如细胞，它无时无刻不在进行新陈代谢，吃下食物， 然后把代谢的产物排出体外，这是大自然的精妙设计。但今天，人类已经开始掌握其中的奥秘，把它变成了工业生产的一个环节。生物制造，就是科学家 们把这些微小生物体的内部，变成一个小工厂，吃下原材料，生产出我们需要的产品，比如把秸秆变成环保材料，把二氧化碳变成饲料蛋白，把贝壳做成 牙齿修复材料。这不是一个变魔法的过程，而是以生物工程、基因工程等科学技术为源 ...

12月18日，2025生物制造大会在重庆举办。会上发布的数据显示，目前，我国生物制造产业总规模达到 1.1万亿元，生物发酵产品产量占全球70%以上。 国家注册审核员、广东更佳昊国际认证有限公司总经理李锦堤对《证券日报》记者表示，万亿元规模展 现出我国生物制造产业的强大实力与深厚积累。作为战略性新兴产业，生物制造的发展壮大不仅能催生 新的经济增长点，还能带动医药、化工、燃料等领域协同创新，为提升国家竞争力、应对全球挑战提供 了强劲动能。 多方共筑产业生态 生物制造是以工业生物技术为核心，利用基因工程、合成生物学等技术，通过微生物、酶或细胞等生物 体进行物质加工与转化的制造模式，其应用范围涵盖生物医药、新材料、新能源、生态环保及现代农业 等多个领域，具有低碳循环、绿色清洁特征。 医疗健康方面，武汉禾元生物科技股份有限公司基于水稻胚乳细胞生物反应器的表达体系开发了多款医 药产品。今年7月份，公司旗下I类创新药产品奥福民 重组人白蛋白注射液（水稻）成功入选2024年生 物制造标志性产品名单（第一批）名单。 生物材料方面，上海凯赛生物技术股份有限公司深耕新型生物基材料领域，其开发的生物基聚酰胺连续 纤维增强复合材料强度 ...

从国际技术首创到国内、国际标准引领，从生物材料到生命材料，锦波生物凭借先发优势、原始创新能 力等构筑起业内"牌照壁垒"。面对行业竞争愈发激烈的情况，公司将完善产品矩阵和渠道，致力于建设 国际一流的科技创新型生物材料企业。 核心产品不断突破 在公司展厅内，锦波生物副总经理陆晨阳举起红蓝相间的模型，展示了重组Ⅲ型人源化胶原蛋白的原子 三螺旋结构。公司2018年通过生物合成的方式，在国际上首次发现、解析了Ⅲ型胶原蛋白核心功能区原 子结构，即呈现164.88°柔性弯曲的三螺旋结构。 "正是依托'164.88°根技术'，锦波生物不断进行技术升级，推出新产品。"陆晨阳介绍，公司的"全人源 化胶原蛋白新材料"是我国首个有自主知识产权的原创型新型生物材料。公司还首次实现了广谱抗HPV 生物蛋白、广谱抗新冠病毒多肽药物的产业化及终端产品开发。 锦波生物被称为A股"重组人源化胶原蛋白第一股"。自2021年公司第一张重组人源化胶原蛋白三类医疗 器械注册证获批至今，锦波生物独揽三张重组人源化胶原蛋白三类医疗器械注册证，实现了冻干纤维、 溶液、凝胶全剂型覆盖。 今年9月，锦波生物"重组Ⅲ型人源化胶原蛋白冻干纤维"正式获得国家药监局药品 ...

Core Insights - The article discusses the recent announcement by COFCO Technology regarding a new investment project aimed at expanding its starch sugar production capacity and entering the functional sugar market [1][2]. Project Progress - COFCO Technology plans to invest 880 million yuan to construct a new facility in Pingliang, Gansu Province, with a production capacity of 250,000 tons/year of starch sugar and 10,000 tons/year of D-alloheptulose [1]. - The construction period for the project is set to be 20 months from the board's approval to trial production [1]. - The project will include various facilities such as starch sugar workshops, D-alloheptulose workshops, bottling workshops, wastewater treatment systems, and finished product warehouses [1]. Strategic Importance - This project aligns with COFCO Technology's "14th Five-Year" development strategy and aims to fill the gap in the starch sugar market in the northwest region of China [2]. - The development of D-alloheptulose products is seen as a key direction for COFCO Technology to cultivate new productive forces and expand into strategic emerging industries [2]. Financial Performance - In Q3 2025, COFCO Technology reported a revenue of 4.449 billion yuan, a year-on-year decrease of 14.65%, and a net loss attributable to shareholders of 28.06 million yuan, an increase of 45.91% compared to the previous year [3]. - For the first three quarters of 2025, the company achieved a revenue of 13.262 billion yuan, down 12.31% year-on-year, while the net profit attributable to shareholders was 79.186 million yuan, a significant increase of 724.42% [3].

Core Viewpoint - The article highlights the journey of Shanxi Jinbo Biopharmaceutical Co., Ltd. and its founder Yang Xia, who has dedicated 17 years to developing recombinant type III humanized collagen technology, achieving a breakthrough in "zero immune rejection" and positioning China as a leader in the "life materials" sector [1][12][17]. Group 1: Industry Challenges and Innovations - The article identifies the long-standing challenges in the animal collagen industry, particularly the issue of immune reactions, which has hindered progress for over a century [4][6]. - Yang Xia's approach focuses on overcoming three major obstacles: immune response, virus risk, and purification difficulties, which are seen as significant barriers to industry advancement [6][7]. - The company aims to shift from imitation to original innovation, emphasizing the need for proprietary technology rather than mere replicas in the Chinese industry [7][11]. Group 2: Breakthroughs and Achievements - A pivotal moment for the company occurred in 2018 when the team identified the key structural parameter of recombinant type III humanized collagen, which is 164.88°, marking a significant advancement in understanding this life material [11]. - The company has faced over 1,600 failures in its research journey, but ultimately recognized the self-assembly characteristics of collagen, which helped change perceptions in the medical community [11][12]. - Jinbo has now become a standard setter in the industry, with the international standard for recombinant humanized collagen officially established in April 2025 [12][17]. Group 3: Future Vision and Goals - Yang Xia envisions the company as a "pioneer in life materials," aiming to solidify its global lead and become a top player in the biomaterials sector within the next 10-20 years [15][17]. - The company maintains a sense of urgency and competitive spirit, recognizing the need for continuous innovation to sustain its advantages in the market [15][17]. - The narrative of Jinbo's transformation from a "shell company" to an international standard setter exemplifies the broader trend of China's biopharmaceutical industry moving from a follower to a leader [17].

Core Viewpoint - The construction of key projects in the province is being accelerated before the winter season, with significant progress reported in various sites [2] Group 1: Project Overview - The Dongrui Biomaterials Industry Chain Project in Dalian's Songmu Island Chemical Industry Development Zone has completed the main structure of its first phase [2] - The project has a total investment of 2 billion yuan, funded by Shanghai Dongrui New Materials Co., Ltd [2] - Since its commencement in May, the project has received strong support from the Pu Wan Economic Zone to enhance construction efficiency [2] Group 2: Project Timeline - The first phase of the Dongrui project is expected to be completed by the second quarter of next year and will reach trial production conditions [2]

Core Insights - The article highlights the significant progress made by Benxi City in promoting high-value patents and enhancing the overall service efficiency in intellectual property management [1][2][3] Group 1: High-Value Patent Development - Benxi City has implemented a strong intellectual property strategy focusing on high-quality development, achieving a per capita high-value invention patent ownership of 3.09 by June 2023, with an annual growth rate of 30% [1] - The proportion of high-value invention patents in Benxi has increased to 52.5%, surpassing the average level in Liaoning Province [1] Group 2: Support for Enterprises - The city actively supports leading enterprises like Benxi Steel and Liaoning Aierchuang Biological Materials Co., Ltd. in applying for overseas patents through the PCT route, creating a "patent moat" for international markets [2] - Benxi has facilitated the transformation of intellectual property from intangible assets to tangible productivity, encouraging industrial application and effective matching of innovation results with market demands [2] Group 3: Intellectual Property Protection - Benxi City has established a high-standard intellectual property protection framework, including strict enforcement and credit supervision, to create a fair and predictable business environment [3] - The city has taken action against trademark and patent infringements, with nine trademark infringement cases and four patent infringement disputes resolved to date [3] Group 4: Public Service System - The city is building a convenient public service system for intellectual property, collaborating with provincial and municipal centers to provide specialized guidance and services to enterprises [4][5] - Benxi has introduced a financial responsibility reform plan in the intellectual property sector, enhancing grassroots engagement and motivation in intellectual property work [5]

Core Viewpoint - The company Jiangyin Beirisen Biochemical Technology Co., Ltd. is leading the development of mussel adhesive protein for medical applications, having recently completed a new round of equity financing to accelerate clinical development of its products [1] Group 1: Original Research Breakthroughs - Mussel adhesive protein, extracted from mussels, is recognized for its anti-inflammatory and immune barrier reconstruction properties, earning it the title of "marine soft gold" [3] - Beirisen is the first company globally to apply mussel adhesive protein in the medical field, establishing a full industry chain from laboratory research to market commercialization since its founding in January 2011 [5] Group 2: New Medical Aesthetic Injection Market - Beirisen has overcome three major global challenges in the production of mussel adhesive protein: purification difficulty, high costs, and storage at room temperature [7] - The company has successfully purified mussel adhesive protein to over 70% medical-grade standards and achieved a three-year room temperature storage capability [7] - Beirisen has filed over 100 patents covering the entire process from raw material preparation to clinical application, with its Class III medical device for intradermal injection showing significant efficacy in anti-inflammatory repair and wound healing [7] Group 3: Capital and Industry Dual-Drive - The recent financing will focus on three main areas: accelerating clinical transformation of multiple product lines, building a closed-loop full industry chain, and deepening international research cooperation [11] - Beirisen aims to establish its own GMP-standard production workshop and cold chain logistics system to control the entire process from raw material preparation to end products [11] - The company is transitioning from a regional innovative enterprise to a globally competitive original manufacturer of biomaterials, expanding the application of mussel adhesive protein from single applications to multi-scenario medical solutions [11]

Core Viewpoint - The Guangzhou Baiyun District is launching a three-year action plan (2026-2028) to accelerate the high-quality development of the biomanufacturing industry, establishing a comprehensive ecosystem to enhance the sector's competitiveness and output [1][2]. Group 1: Action Plan and Ecosystem - The action plan outlines the construction of a "11221" industrial ecosystem, which includes the establishment of 1 biomanufacturing innovation center, 1 pilot base, 2 achievement transformation platforms, two phases of over 1,000 acres of biomanufacturing industrial parks, and a biomanufacturing fund cluster with a scale of 100 billion [1][2]. - The goal is to drive the output value of related biomanufacturing industries to exceed 50 billion by 2028, positioning the area as a leading biomanufacturing hub with national competitiveness [1]. Group 2: Capital and Project Collaboration - A biomanufacturing fund cluster with a total scale of 10 billion has been established, led by Baiyun Investment Group and supported by various top investment institutions and industry leaders, aiming to create a "state-owned enterprise leading + professional fund management + industry enterprise collaboration" structure [2]. - The first phase of the fund has completed a 1 billion fundraising, covering the entire lifecycle of biomanufacturing enterprises from startup to Pre-IPO [2]. Group 3: Project Signings - The event featured significant project signings in areas such as biomedicine, biomaterials, and biocosmetics, including plans for a cell culture medium and CDMO production base by Auscon Biotech, and a core component R&D and production base for mass spectrometers by Shandong Yingsheng Biotech [2]. - Blue Bay Technology will develop a biomanufacturing industrial park that integrates R&D, pilot testing, and production, providing systematic services for technology transformation and enterprise growth [2]. Group 4: Ongoing Support - Guangzhou's municipal departments will continue to support Baiyun District in leveraging its industrial foundation and innovative resources to implement biomanufacturing development policies and facilitate the transformation of more research outcomes [3].

Core Viewpoint - The Guangzhou Baiyun District has launched a three-year action plan (2026-2028) to accelerate the high-quality development of the biomanufacturing industry, aiming to achieve an output value exceeding 50 billion yuan by 2028 and establish a nationally competitive biomanufacturing industry pilot zone [1][2]. Group 1: Industry Development Plan - The action plan outlines the construction of a "11221" industrial ecosystem, which includes the establishment of one biomanufacturing innovation center, one pilot base, two achievement transformation platforms, two phases of over 1,000 acres of biomanufacturing industrial parks, and a biomanufacturing fund cluster with a scale of 10 billion yuan [2][3]. - The biomanufacturing sector is recognized as a core area for cultivating new productive forces and is a strategic competitive point for the nation [1][2]. Group 2: Current Industry Landscape - Baiyun District is a significant hub for the cosmetics industry, with over 1,200 licensed cosmetics manufacturing enterprises, accounting for about 20% of the national total, and an industry scale projected to reach 36.14 billion yuan by 2024 [2]. - The biopharmaceutical industry in the region has surpassed 31.1 billion yuan, featuring leading companies such as Guangzhou Pharmaceutical Group and Hutchison Whampoa, fostering a collaborative development advantage through "leading enterprises + research empowerment + stock upgrading" [2]. Group 3: Industrial Park and Investment - The Guangzhou Baiyun Biomanufacturing Industrial Park, as a core component of the "11221" system, is crucial for spatial layout and cluster development, with the first phase covering approximately 450 acres focused on biomedicine, cell genes, and beauty products, while the second phase will cover about 900 acres across five major industry groups [3]. - A biomanufacturing industry fund cluster with a total scale of 10 billion yuan has been established, with the first phase raising 1 billion yuan, targeting investments across the entire lifecycle of biomanufacturing enterprises from startup to Pre-IPO [3].